Skip to main content

Table 1 Characteristics of the BCAC European study participants

From: Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy

Characteristics

ER-negative patients who received chemotherapy

Percent

ER-negative patients who did not receive chemotherapy

Percent

ER-positive patients who received chemotherapy

Percent

Number of patients

1499

100.00

835

100.00

3151

100.00

Age at diagnosis (mean ± SD, years)

51.69 ± 10.85

59.46 ± 12.18

51.74 ± 9.88

Family history

      

 No

974

64.98

457

54.73

2233

70.87

 Yes

275

18.35

148

17.72

596

18.91

Missing

250

16.68

230

27.54

322

10.22

Tumor stage

      

 1

356

23.75

401

48.02

606

19.23

 2

804

53.64

259

31.02

1751

55.57

 3

182

12.14

58

6.95

526

16.69

 Missing

157

10.47

117

14.01

268

8.51

Histological grade

      

 Well-differentiated

23

1.53

97

11.62

390

12.38

 Moderately differentiated

293

19.55

310

37.13

1624

51.54

 Poorly/undifferentiated

1183

78.92

428

51.26

1137

36.08

Tumor size

      

 ≤2 cm

664

44.30

528

63.23

1387

44.02

 ≥2 cm to ≤5 cm

744

49.63

271

32.46

1490

47.29

 ≥5 cm

91

6.07

36

4.31

274

8.70

Lymph node status

      

 Negative

735

49.03

651

77.96

976

30.97

 Positive

764

50.97

184

22.04

2175

69.03

PR status

      

 PR-negative

1271

84.79

633

75.81

546

17.33

 PR-negative HER2-negative

692

46.16

315

37.72

304

9.65

  1. Results are presented as number of patients unless stated otherwise. BCAC, Breast Cancer Association Consortium; ER, estrogen receptor; PR, progesterone receptor; SD, standard deviation; HER2, human epidermal growth factor receptor 2.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us